Share on LinkedInShare on LinkedIn

ARTICLE · 05 JULY 2024

Reverse Payment Settlement Disclosure At USPTO

Steptoe LLP
Steptoe LLP
Contributor
Steptoe LLP

Steptoe LLP

Steptoe International (UK) LLP has built a strong reputation for providing top-quality regulatory,...

View firm profile
Explore more from Steptoe LLP

On April 19, 2024, the U.S. Patent and Trademark Office (USPTO) issued a Federal Register notice requesting public comment on a variety of proposed changes to the rules governing...

United StatesAntitrust/Competition Law

On April 19, 2024, the U.S. Patent and Trademark Office (USPTO) issued a Federal Register notice requesting public comment on a variety of proposed changes to the rules governing the way that it handles certain patent challenges. Most significantly, the proposed changes would require more patent litigants to disclose private settlement agreements to the USPTO, which in the pharmaceuticals and other contexts could lead to greater FTC scrutiny of reverse payment agreements and may have a chilling effect on litigation resolutions.

Background

Over the past decade and more, one of the hottest topics in antitrust circles has been whether and when private parties' settlement of certain types of patent-related disputes raises antitrust concerns. Though patent-related antitrust issues can arise in virtually any industry, much of the attention has focused on resolution of pharmaceutical patent disputes. In particular, attention has centered on the potential anticompetitive

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from